Даваа–Баасан 08:30–20:00 · Бямба 09:00–16:00
Now showing 1 - 2 of 2
  • Some of the metrics are blocked by your 
    Item type:Publication,
    Determination of Antimicrobial Activity of Antibiotics Encapsulated in Liposomes
    (Mongolian National University of Medical Sciences, 2024-03-15)
    Erdene, Enkhtaivan
    ;
    ; ;
    Objective: Antibiotic-resistant infections caused by bacteria are already a serious concern for humanity, and by 2050, they are most likely to overtake all other causes of death. One of the most frequent causes of skin infections is methicillin-resistant Staphylococcus aureus (MRSA), whose resistance to most medications makes treatment challenging. This study aimed to determine the antibacterial activity of liposome-encapsulated doxycycline compared to free doxycycline. Methods: This study was conducted using an experimental design. Our study isolated and purified the phospholipid (PL) fraction from egg yolk. Antibiotics were encapsulated using the freeze-thaw process, and phospholipids were extracted via intermittent evaporation. Finally, the liposome's minimum inhibitory concentration (MIC) was effective against MRSA. Results: Phospholipid fraction isolated from egg yolks with 32% extraction yield of phosphatidylcholine. The thin phase chromatography fraction was phospholipids with a retention factor (Rf) of 0.39. The effectiveness of liposomal doxycycline hyclate over free doxycycline was demonstrated by in vitro tests. Conclusion: The results showed that a liposome containing phosphatidylcholine could be a tremendous topical antimicrobial construct for treating MRSA infections.
  • Some of the metrics are blocked by your 
    Item type:Publication,
    Evaluation of Liposome-Encapsulated Vancomycin Against Methicillin-Resistant Staphylococcus aureus
    (MDPI AG, 2025-02)
    Erdene, Enkhtaivan
    ;
    Munkhjargal, Odonchimeg
    ;
    ; ;
    Background/Objectives: Methicillin-resistant Staphylococcus aureus (MRSA) is a global health concern due to its resistance to conventional antibiotics. This study evaluated the efficacy of liposome-encapsulated vancomycin against MRSA using phospholipids extracted from egg yolk. Liposomes were prepared via the freeze-thaw method, yielding vesicles with an average diameter of 157.01 ± 33.04 nm and a polydispersity index (PDI) of 0.0442, indicating uniformity and stability. Antibacterial activity was assessed using the microdilution method. Liposome-encapsulated vancomycin demonstrated complete bacterial growth inhibition (100%) against MRSA ATCC 2758 at dilutions of 101 and 102, compared to only 50% inhibition by free vancomycin at 101. At higher dilutions (103), liposome-encapsulated vancomycin maintained 70% inhibition, whereas free vancomycin was ineffective. In vivo studies using a murine wound infection model revealed that wounds treated with liposome-encapsulated vancomycin achieved superior healing, with complete tissue regeneration observed by day 14. Histological analysis showed reduced inflammation and enhanced tissue recovery in liposome-encapsulated vancomycin-treated groups, compared to fibrosis and persistent necrosis in free vancomycin-treated groups. By enabling sustained drug release and improved bioavailability, liposomal formulations minimized required dosages and systemic toxicity, reducing the risk of resistance development. This study highlights the clinical potential of liposome-encapsulated vancomycin as a scalable, cost-effective treatment for MRSA, particularly in resource-limited settings.
    Scopus© Citations 8